Roche partners with Upsher-Smith to develop novel VAP-1 inhibitor

Swiss global pharma giant Roche (ROG:SIX) has joined forces with Proximagen, a wholly-owned UK subsidiary of Upsher-Smith Laboratories, to further develop a novel, oral small molecule inhibitor of Vascular Adhesion Protein 1 (VAP-1).

The VAP-1 inhibitor is currently in Phase II clinical development.

Sophie Kornowski-Bonnet, head of Roche Partnering, said: “This agreement is a novel partnering model where regulatory responsibility and trial sponsorship will only transition upon the success of additional clinical studies. A dedicated and very experienced team, located at the Roche Innovation Center New York, will drive the development most efficiently from our side.”